AstraZeneca shares drop after company announces 'routine' safety pause in coronavirus vaccine trial

AstraZeneca shares drop after company announces ‘routine’ safety pause in coronavirus vaccine trial

106654934 1596840976763 gettyimages 1264548698 a66i1673 2020080731708558
A small bottle labeled with a “Vaccine” sticker is held near a medical syringe.
AstraZeneca shares fell more than 6% in after-hours trading Tuesday after the company said its late-stage trial for a potential coronavirus vaccine had been put on hold due to safety concerns.”This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials, In large trials illnesses will happen by chance but must be independently reviewed to check this carefully,” the company said in a statement to CNBC.

It said it was trying to expedite the review to “minimize any potential impact on the trial timeline.”

An individual familiar with the development said researchers were told the hold was placed on the trial out of “an abundance of caution” after a suspected serious adverse reaction in a participant in the United Kingdom, according to STAT News.

It’s unclear how long the hold on the trial will last. AstraZeneca began its trial late last month and is one of three companies currently in late-stage testing for a potential vaccine. The other two are Pfizer and Moderna, which both began their trials in late July.

In July, the company published data that showed its vaccine produced a promising immune response in an early-stage trial.

The vaccine was found to be well-tolerated and there were no serious adverse events, according to the researchers at the time. Fatigue and headache were the most commonly reported, they said. Other common side effects included pain at the injection site, muscle ache, chills and a fever

Credit: CNBC

Leave A Comment

Your email address will not be published. Required fields are marked *